Prognostic effect of programmed cell death ligand 1/programmed cell death 1 expression in cancer stem cells of human oral squamous cell carcinoma

被引:1
|
作者
Todoroki, Keita [1 ,2 ]
Abe, Yushi [1 ,2 ]
Matsuo, Katsuhisa [1 ,2 ]
Nomura, Hidetoshi [1 ]
Kawahara, Akihiko [3 ]
Nakamura, Yoshiaki [4 ]
Nakamura, Moriyoshi [1 ]
Seki, Naoko [1 ]
Kusukawa, Jingo [1 ]
机构
[1] Kurume Univ, Dent & Oral Med Ctr, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan
[2] Kouhoukai Med Corp, Takagi Hosp, Dept Dent & Oral Surg, Okawa, Fukuoka 8310016, Japan
[3] Kurume Univ Hosp, Dept Diagnost Pathol, Kurume, Fukuoka 8300011, Japan
[4] Oita Saiseikai Hita Hosp, Dept Dent & Oral Surg, Hita, Oita 8771292, Japan
关键词
CSC; OSCC; CD44v3; CD24; programmed cell death ligand 1; programmed cell death 1; immune checkpoint inhibitors; HEAD; PD-L1; CD24; IDENTIFICATION; IMMUNOTHERAPY; POPULATION; RECURRENT;
D O I
10.3892/ol.2024.14213
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The relationship between cancer stem cells (CSCs) in oral squamous cell carcinoma (OSCC) and programmed cell death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) remains unclear. Therefore, the present study aimed to clarify the association between the CD44v3(high)/CD24(low) immunophenotype of CSCs in OSCC and PD-L1/PD-1 co-expression, and to assess the prognostic effect of CSCs in terms of immune checkpoint molecules. Formalin-fixed, paraffin-embedded tissue samples and clinicopathological data from 168 patients with OSCC were retrospectively retrieved. Immunohistochemical staining and reverse transcription quantitative polymerase chain reaction were applied to a tissue microarray of the invasive front of each case. Semi-automated cell counting was used to assess CD44v3, CD24, PD-L1 and PD-1 expression by immunohistochemistry (IHC) using a digital image analysis program. Associations between immunological markers and clinicopathological variables were estimated. Patients with the CSC immunophenotype CD44v3(high)/CD24(low), and patients with a high PD-L1/PD-1-positive cell density in the tumor parenchyma and stroma had significantly lower survival rates. Furthermore, patients with the CSC immunophenotype (CD44v3(high)/CD24(low)) and high PD-L1/PD-1 co-expression had even lower survival rates (P<0.01, log-rank test). Notably, there was a positive correlation between CD44v3 and PD-L1 expression (tau=0.1096, P=0.0366, Kendall rank correlation coefficient) and a negative correlation between CD24 and PD-1 expression (tau=-0.1387, P=0.0089, Kendall rank correlation coefficient). Additionally, the high CD44v3 expression group, as determined by IHC, exhibited significantly decreased expression of U2 small nuclear RNA auxiliary factor 1 (U2AF1) at the mRNA level compared with that in the low CD44v3 expression group (P<0.001, Mann-Whitney U test), and U2AF1 and PD-L1 mRNA expression exhibited a significant negative correlation (tau=-0.3948, P<0.001, Kendall rank correlation coefficient). In conclusion, CSCs in OSCC may evade host immune mechanisms and maintain CSC stemness via PD-L1/PD-1 co-expression, resulting in unfavorable clinical outcomes.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Programmed Cell Death Ligand 1 Immunoexpression in Head and Neck Squamous Cell Carcinoma: A Narrative Review of Considerations for the Histopathologist
    Kala, Pooja Sharma
    Thapliyal, Naveen Chandra
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2024, 18 (02) : EE1 - EE6
  • [32] Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability
    Montella, Marco
    Sabetta, Rosalaura
    Ronchi, Andrea
    De Sio, Marco
    Arcaniolo, Davide
    De Vita, Ferdinando
    Tirino, Giuseppe
    Caputo, Alessandro
    D'Antonio, Antonio
    Fiorentino, Francesco
    Facchini, Gaetano
    Di Lauro, Giovanni
    Perdona, Sisto
    Ventriglia, Jole
    Aquino, Gabriella
    Feroce, Florinda
    Dos Reis, Rodolfo Borges
    Neder, Luciano
    Brunelli, Matteo
    Franco, Renato
    Marino, Federica Zito
    FRONTIERS IN MEDICINE, 2022, 9
  • [33] Programmed Death-Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Temporal Bone Squamous Cell Carcinoma
    Hongo, Takahiro
    Kuga, Ryosuke
    Miyazaki, Masaru
    Komune, Noritaka
    Nakano, Takafumi
    Yamamoto, Hidetaka
    Koike, Kensuke
    Sato, Kuniaki
    Kogo, Ryunosuke
    Nabeshima, Kazuki
    Oda, Yoshinao
    Nakagawa, Takashi
    LARYNGOSCOPE, 2021, 131 (12) : 2674 - 2683
  • [34] Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type
    Jo, Jae-Cheol
    Kim, Misung
    Choi, Yunsuk
    Kim, Hyun-Jung
    Kim, Ji Eun
    Chae, Seoung Wan
    Kim, Hawk
    Cha, Hee Jeong
    ANNALS OF HEMATOLOGY, 2017, 96 (01) : 25 - 31
  • [35] A Comparative Study to Assess the Increased Expression of Programmed Cell Death-1 (PD1) and Programmed Cell Death- Ligand-1 (PDL1) in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma
    Srivastava, Sonalika
    Sinha, Abhishek
    Srivastava, Sunita
    Mishra, Anuj
    JOURNAL OF INDIAN ACADEMY OF ORAL MEDICINE AND RADIOLOGY, 2023, 35 (04) : 468 - 472
  • [36] Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma
    Mikami, Shuji
    Mizuno, Ryuichi
    Kondo, Tsunenori
    Shinohara, Nobuo
    Nonomura, Norio
    Ozono, Seiichiro
    Eto, Masatoshi
    Tatsugami, Katsunori
    Takayama, Tatsuya
    Matsuyama, Hideyasu
    Kishida, Takeshi
    Oya, Mototsugu
    CANCER SCIENCE, 2019, 110 (06) : 1820 - 1828
  • [37] Association of Programmed Death Ligand-1 Overexpression with the Grade and Stage of Oral Squamous Cell Carcinoma
    Qureshi, Zeeshan Mustafa
    Qamar, Samina
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2020, 30 (06): : 662 - 664
  • [38] Programmed cell death 1 and programmed cell death ligand 1 expression in invasive breast carcinoma using CAL10 and NAT105 immunostaining
    Durak, Ozlem
    Bozkurt, Kemal Kursat
    Ciris, Ibrahim Metin
    Kocer, Murat
    Eroglu, Hasan Erol
    BIOTECHNIC & HISTOCHEMISTRY, 2023, 98 (02) : 147 - 154
  • [39] Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
    Zhao, Jing
    Huang, Jian
    CHINESE MEDICAL JOURNAL, 2020, 133 (07) : 853 - 862
  • [40] Comparative analysis of programmed cell death ligand 1 assays in renal cell carcinoma
    Lee, Kyu Sang
    Choe, Gheeyoung
    Yun, Sumi
    Lee, Kyoungyul
    Moon, Seyoung
    Lee, Sangchul
    Hong, Sung Kyu
    Byun, Seok-Soo
    Lee, Sang Eun
    HISTOPATHOLOGY, 2020, 77 (01) : 67 - 78